Current location:


Choose your location:

WHO Meeting Held to Review the Results of Sinovac SARS Vaccine Phase I Trial and Discuss Phase II Protocols

Translated and summarized by Sinovac, from NIBPCP Chinese website

Geneva -- On June 1 2005 the Initiative for Vaccine Research (IVR), a division of World Health Organization (WHO), organized a conference to review the results of the Phase I SARS vaccine trial and discuss Phase II protocol at WHO headquarters in Geneva . Dr. Marie-Paule Kieny Director of IVR hosted the meeting, which was attended by seven WHO professionals, and representatives from the National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) and Sinovac Biotech Ltd. The NICPBP representatives included Mr. Guanmu Dong, director of NIBPCP, and Mr. Junzhi Wang, deputy general director of NICPBP. Representatives from Sinovac were Ms. Nan Wang, vice president of Sinovac, and Dr. Hong Gao, medical manager of Sinovac.

Dr.Gao gave a presentation about the Phase I clinical trial results of Sinovac’s SARS vaccine, and a draft proposal for conduction Phase II clinical trials. After detailed discussions, the WHO representatives expressed to the general audience, their satisfaction with the results of the phase I trial. The second topic of discussion was on the protocol of Phase II trial. The WHO professionals gave several valuable technical recommendations on Phase II trial.


Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis.

SINOVAC's COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The Healive®, a hepatitis A vaccine manufactured by the Company, passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine, that was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) was prequalified by WHO.

SINOVAC was the first company that granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC has been continually dedicating itself to new vaccine research and development, with more combination vaccine products in the pipeline, and constantly exploring opportunities in the international market. SINOVAC looks forward to conducting more extensive and in-depth trade and cooperation with more countries, enterprises, and professional institutions.

For more information, please see the Company’s website at


Sinovac Biotech Ltd.

Helen Yang

+86-10-8279-9871 or


Fax: +86-10-6296-6910

ICR Inc.

Bill Zima

U.S.: 1-646-308-1707